Kombiglyze XR 5mg/500mg Tablet is a fixed-dose combination medication containing Saxagliptin 5mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby improving glycemic control through increased insulin secretion and decreased glucagon release in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, enhancing insulin sensitivity, and promoting peripheral glucose uptake. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining steady plasma concentrations. Kombiglyze XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly in patients inadequately controlled on metformin alone or saxagliptin alone. It should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of renal function and glycemic parameters is recommended during therapy to optimize efficacy and safety.